IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other research firms also recently weighed in on IPCI. Maxim Group set a $6.00 price target on IntelliPharmaCeutics Intl and gave the company a “buy” rating in a research note on Thursday, May 11th. Aegis restated a “buy” rating and issued a $8.00 price target on shares of IntelliPharmaCeutics Intl in a research note on Monday, February 13th. Finally, Zacks Investment Research upgraded IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a research note on Tuesday, March 21st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $4.63.

Shares of IntelliPharmaCeutics Intl (NASDAQ:IPCI) traded down 1.03% on Friday, hitting $1.93. The company’s stock had a trading volume of 53,045 shares. IntelliPharmaCeutics Intl has a 1-year low of $1.41 and a 1-year high of $3.35. The company has a 50 day moving average of $2.08 and a 200 day moving average of $2.52. The firm’s market cap is $58.64 million.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at

A hedge fund recently raised its stake in IntelliPharmaCeutics Intl stock. First Foundation Advisors raised its position in shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) by 172.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 274,592 shares of the company’s stock after buying an additional 173,692 shares during the period. First Foundation Advisors owned approximately 0.90% of IntelliPharmaCeutics Intl worth $686,000 at the end of the most recent reporting period. 1.49% of the stock is currently owned by hedge funds and other institutional investors.

IntelliPharmaCeutics Intl Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

12 Month Chart for NASDAQ:IPCI

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for IntelliPharmaCeutics Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl Inc and related companies with's FREE daily email newsletter.